2253 results about "Excipient" patented technology

The invention relates to the technical field of medicine quality detection, and particularly discloses an optical detection method and system for the content of vitamin tablets. The method comprises the following steps: driving an optical fiber probe array to carry out three-dimensional multi-angle near-infrared scanning through a multi-axis mechanical arm, and collecting reflection spectrum data; a weighted spectrum is generated through derivative spectrum analysis and double evaluation, and auxiliary material noise is corrected and separated in combination with subspace projection and a dynamic kernel function; performing spectral vector projection and regression coefficient iterative optimization through an online PLS model, and synthesizing an error coefficient based on a four-level index retrieval standard library to perform dual-channel feedback; and finally, fusing the credibility weight to output a detection result of the binding confidence. The method realizes nondestructive and high-precision detection of the vitamin tablets, has the beneficial effects of multi-dimensional data fusion, dynamic error compensation and high model adaptability, and remarkably improves the detection accuracy and reliability.

The invention relates to a sodium channel regulator for inhibiting Nav1.8, and provides a compound as shown in a formula I which can be used as the sodium channel regulator for inhibiting Nav1.8, and an isomer of the compound, or a pharmaceutically acceptable salt of the compound, the invention also provides a pharmaceutical composition containing the compound and the isomer thereof, or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The invention relates to a ligand-effector moiety provided with at least one saponin and antibody-effector moiety provided with at least one saponin. An aspect of the invention is a composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention. The invention also relates to an antibody-drug conjugate comprising covalently linked saponin and to an antibody-oligonucleotide conjugate comprising covalently linked saponin. An aspect of the invention relates to a pharmaceutical composition comprising the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention, and optionally further comprising a pharmaceutically acceptable excipient. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin, for use as a medicament. The invention also relates to the ligand-effector moiety provided with at least one saponin or the antibody-effector moiety provided with at least one saponin of the invention for use in the treatment or prophylaxis of a cancer.

The invention discloses a preparation method of perindopril amlodipine tablets, and belongs to the field of pharmacy. The perindopril amlodipine tablet is prepared from the following raw material medicines: arginine perindopril and amlodipine besylate and auxiliary materials: lactose, microcrystalline cellulose, hydrophobic colloidal silicon dioxide and magnesium stearate. The preparation method of the perindopril amlodipine tablet comprises the following steps: weighing according to the prescription amount, crushing and sieving the raw materials for pretreatment, sieving the whole particles of the auxiliary materials for pretreatment, premixing, feeding and total mixing, tabletting and the like. The prepared perindopril amlodipine tablet is relatively good in quality, high in stability and relatively few in waste products.

The invention relates to the field of biotechnology and female health care, in particular to a stachyose composition for promoting micro-ecological regulation of lactobacillus and application of the stachyose composition, and the composition comprises stachyose and pharmaceutically acceptable auxiliary materials. The stachyose is used as prebiotics to selectively promote proliferation and colonization of the lactobacillus crispatus, the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can promote proliferation of the lactobacillus crispatus, the lactobacillus crispatus is one or more of the lactobacillus crispatus, the lactobacillus plantarum and the lactobacillus acidophilus, and the combination of 1%-5% of the stachyose and 0.1%-0.5% of the lactic acid can inhibit gardnerella and candida albicans. The stachyose composition disclosed by the invention is in the form of slow-release gel and bath foam; the composition can be used for treating or preventing bacterial vaginitis, colpitis mycotica and related symptoms, has the advantages of no antibiotics, no drug resistance, high safety and the like, and is suitable for the fields of vagina local nursing and micro-ecological regulation.

The invention relates to the technical field of traditional Chinese medicine component detection and discloses a rapid detection method for traditional Chinese medicine compound components. The method comprises the following steps: performing Raman spectrum scanning on a traditional Chinese medicine compound sample to generate component spectrum distribution information, and performing fitting by adopting a partial least square algorithm to determine a local component anomaly risk area; meanwhile, atomic force microscopic imaging is carried out, a microstructure distribution map is generated, and a potential component mismatch feature region is marked through texture feature extraction and pattern recognition. And generating a detection optimization adjustment region based on the space coordinates of the region, analyzing the gradient change in the molecular arrangement direction of the region to evaluate the component distribution offset state, and analyzing the interface bonding state of the active component and the auxiliary material to evaluate the component interaction coupling strength. And finally, on the basis of an evaluation result, whether the real-time parameter calibration is started in the detection optimization adjustment area is judged through a dual-channel decision-making mechanism. According to the method, correlation analysis of component spectrums and microtopographies is realized, and the accuracy and pertinence of traditional Chinese medicine compound component detection are improved.

The present invention provides a pharmaceutical composition, the composition comprises a therapeutically effective amount of bumetanib, one or more specific antioxidants and other necessary one or more pharmaceutically acceptable pharmaceutic adjuvants, and the specific antioxidants are selected from one or more of fat-soluble vitamin C derivatives or phenolic antioxidants. In addition, the invention also discloses a method for improving the stability of the bumetanib pharmaceutical composition. According to the technical scheme, the problems of generation and growth of N-nitroso bumetanib and other related substances in the production and storage process of the bumetanib solid preparation are effectively solved, and the drug stability and the medication safety are remarkably improved.

The invention relates to the technical field of oral membranes, in particular to a multilayer oral membrane and a preparation method thereof. The invention provides an oral membrane composition, which comprises semeglutide and pharmaceutically acceptable auxiliary materials, and is characterized in that the composition is formed by combining a drug-containing biological adhesion layer and a backing layer, and the backing layer mainly comprises a membrane forming material, a solvent and a plasticizer; the drug-containing biological adhesion layer mainly comprises semeglutide, a film-forming material, an adhesive, a pH regulator, a flavoring agent and a solvent. By preparing the double-layer oral membrane, the semeglutide is administrated through the oral cavity, and after the insoluble or slowly eroded / dissolved backing layer (preventing saliva from dissolving the medicine) and the adhesive layer containing the main medicine are combined together, the one-way delivery of the main medicine can be realized; through experiments, it is accidentally found that when temperature-sensitive materials such as poloxamer are added to be combined with a conventional adhesive for use, the residence time of the medicine in the oral mucosa can be remarkably prolonged, the curative effect of the medicine is improved, and the main mechanism is that after the medicine is administered, in the oral temperature environment, after the medicine makes contact with mucus on the surface of the oral mucosa, the oral mucosa does not adhere to the oral mucosa. And after the entanglement and piling effects among poloxamer micelles are intensified to form gel, the gel and a conventional adhesive are cooperated to improve the adhesion between the oral membrane and the oral mucosa. Besides, the medicine can be removed at any time, blood sugar can be better controlled, T2DM complications can be better reduced, a more ideal taking mode is provided for weight loss patients, and a new administration mode is provided for reducing blood sugar and reducing weight. The prepared oral cavity membrane is small in size, light in weight, thin, convenient to apply, carry and transport, safe and environmentally friendly to use and capable of meeting the requirements of old people and travelers.

A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

The invention relates to the technical field of female private care, and discloses a long-acting antibacterial female care gel and a preparation method thereof.According to the care gel, natural plant extracts serve as core active ingredients, microbial fermentation products, macromolecular thickening agents and functional auxiliary materials are supplemented, and a synergistic system is formed through scientific compatibility; wherein the core components comprise compound antibacterial components such as cranberry extract, gallnut extract and pomegranate peel extract, nourishing and repairing components such as radix puerariae extract and southern dodder seed extract, and stable components such as ammonium polyacryloyldimethyl taurine. By optimizing the formula composition and the preparation process, the technical problems that existing female care gel is short in bacteriostasis time and poor in biocompatibility are solved, and the female care gel has the multiple effects of long-acting bacteriostasis, mildness, no irritation, nourishing, repairing, moisturizing, lubricating and the like. The preparation method adopts the processes of segmented extraction, gradient mixing and low-temperature sterilization, ensures the stability of active ingredients and the uniformity of a gel system, and is suitable for large-scale production.

The invention relates to the technical field of biological medicine, in particular to a composition based on dendrobium nobile, a preparation method of the composition and application of the composition to preparation of soft capsules, buccal tablets and oral soluble film preparations, the composition takes dendrobium nobile extract as a main active ingredient, and can be matched with auxiliary materials such as excipients, disintegrating agents and film-forming agents to be optimized into different dosage forms. The soft capsule has a slow release effect, the buccal tablet is convenient to carry and take, and the oral soluble film can realize rapid oral mucosa absorption. The preparation method disclosed by the invention is stable in process and suitable for industrial production, and the obtained preparation has good bioavailability and stability, can be widely applied to the field of health-care foods or medicines, and is particularly suitable for enhancing immunity, resisting oxidation, moistening lung, promoting salivation and the like.

A topical ophthalmological composition includes a muscarinic receptor antagonist as an active pharmaceutical ingredient; and medium chain triglycerides (MCTs) or light liquid paraffin oil as liquid vehicle. The topical ophthalmological composition treats an ocular disease.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and discloses a traditional Chinese medicine micro-powder capsule based on functions of promoting blood circulation to remove blood stasis, dispelling wind and eliminating dampness and activating meridians to stop pain. 0.8%-1.2% of scorpion; 0.8%-1.2% of Chinese polyphaga; 0.8%-1.2% of safflower carthamus; 0.8%-1.2% of peach kernels; 0.8%-1.2% of zaocys dhumnade; 0.8% to 1.2% of frankincense; 0.8%-1.2% of ligusticum wallichii; 0.8%-1.2% of cortex moutan; 0.8% to 1.2% of myrrh; 0.8%-1.2% of notopterygium root; 0.8%-1.2% of radix angelicae pubescentis; 0.8%-1.2% of fructus lycii; 0.8%-1.2% of centipede; 15%-25% of a functional auxiliary material: 3%-5% of a nano dispersion carrier; and 3%-5% of an inclusion compound. By adopting a beta-cyclodextrin inclusion technology, volatile oil and a humid and hot environment can be effectively isolated, the stability of the volatile oil can be enhanced, by taking ligustrazine as an example, under an accelerated test condition, the retention rate of the ligustrazine in 6 months is up to 89.5%, and compared with a non-inclusion condition, the retention rate is improved, the degradation rate is reduced by 3.1 times, and the stability of the core component for promoting blood circulation to remove blood stasis in the storage and use process is ensured.

The invention discloses granules of a composition containing rhizoma polygonati. The granules comprise the following components in percentage by weight: 30%-50% of composition dry paste powder, 38%-58% of a filling agent, 0.1%-20% of an adhesive and 0.1%-2% of a flow aid, the composition comprises rhizoma polygonati, fructus lycii, flos chrysanthemi and radix glehniae. Wherein the filling agent is dextrin; wherein the adhesive is maltodextrin or povidone; wherein the flow aid is colloidal silicon dioxide. According to the composition disclosed by the invention, proper auxiliary materials and an adding mode thereof are selected, so that the inherent properties of the original extract are improved, the extract is not easy to soften, the caking tendency caused by moisture absorption or heat absorption among particles is avoided, and the caking probability is reduced.

The invention aims to disclose a special dietary preparation based on alpha-ketoglutaric acid as well as a preparation process and application thereof, and relates to the technical field of dietary supplements. Every 800 mg of the dietary preparation comprises 50 mg to 100 mg of alpha-ketoglutaric acid or alpha-ketoglutaric acid salt, 5 mg to 12 mg of N-acetylneuraminic acid or N-acetylneuraminic acid salt, 30 mg to 60 mg of ergothioneine, 100 mg to 150 mg of a desert cistanche deserticola water extract or 50 mg to 80 mg of desert cistanche deserticola total glycosides, and auxiliary materials. The alpha-ketoglutaric acid salt is any one or more of alpha-ketoglutaric acid calcium, alpha-ketoglutaric acid sodium and alpha-ketoglutaric acid magnesium; the N-acetylneuraminic acid salt is any one or more of N-acetylneuraminic acid calcium, N-acetylneuraminic acid sodium and N-acetylneuraminic acid magnesium; the special dietary preparation has the beneficial effects that the special dietary preparation simultaneously contains alpha-ketoglutaric acid or alpha-ketoglutaric acid salt, N-acetylneuraminic acid or N-acetylneuraminic acid salt, ergothioneine and the cistanche deserticola aqueous extract, and has the effects of delaying senescence, resisting fatigue, improving the symptom of kidney-yang deficiency and enhancing immunity for males aged more than 45 years old.

The present disclosure provides a method for treating pain or inflammation in a non-human animal in need thereof. The method comprises administering to a non-human animal a pharmaceutical composition comprising a therapeutically effective amount of grapiprant. Also provided herein are pharmaceutical compositions for treating pain or inflammation in a non-human animal in need thereof. The pharmaceutical compositions comprise a therapeutically effective amount of grapiprant and an excipient, including flavorants.

An active or inactivated recombinant vaccine against COVID-19 is described that comprises a Newcastle disease viral vector and a pharmaceutically acceptable carrier, adjuvant and / or excipient, characterized in that the viral vector is a virus capable of generating a cellular immune response that has a SARS-COV-2 exogenous nucleotide sequence inserted.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

The invention provides sustained-release solid hydrogen peroxide as well as a preparation method and application thereof, and belongs to the technical field of hydrogen peroxide preparation, the sustained-release solid hydrogen peroxide comprises a hydrogen peroxide solution, a stabilizer, an excipient and a sustained-release agent, wherein the slow release agent is a compound of ethyl cellulose and chitosan, and the weight ratio of ethyl cellulose to chitosan is (1-2): 1; the addition amount of the slow-release agent is 0.5%-10% of the total mass of the slow-release solid hydrogen peroxide; according to the invention, ethyl cellulose (hydrophobic barrier) and chitosan (pH response degradation) are combined for use in the sustained-release agent, so that overhigh local concentration caused by concentrated release of hydrogen peroxide is avoided, and the explosion risk is reduced; the preparation method provided by the invention is a crystallization-drying integrated process, the production period can be shortened to 4 hours, while the traditional process needs more than 8 hours, and the energy consumption is reduced by 40%.

The invention provides a metronidazole gel composition and a preparation method thereof, the metronidazole gel composition comprises the following components in percentage by weight: 0.5-1.0% of metronidazole, 0.5-0.7% of benzene-free carbomer, 1.0-5.0% of a humectant, 0.05-0.15% of a preservative, a pH regulator, and / or other pharmaceutically acceptable auxiliary materials, and the balance of water; wherein the metronidazole gel composition does not contain benzene. The metronidazole gel composition is stable in quality and high in safety, particularly, the safety of the gel composition can be further improved by adopting the benzene-free auxiliary material carbomer 980, metronidazole is prevented from making contact with benzene in the long-term external use process, and then the harmfulness of the metronidazole is avoided; moreover, by further optimizing the dosage of carbomer 980, the pH value of the product and the like, the impurities of the product can be better controlled, and the stability of the product is further improved.

The invention belongs to the field of probiotics and application thereof, and particularly relates to a humanized bifidobacterium animalis probiotic strain and application thereof in preparation of drugs for preventing or treating melanoma. The preservation number of the humanized bifidobacterium animalis is GDMCC No: 65044, the preservation unit is called GDMCC for short, and the active metabolite of the humanized bifidobacterium animalis contains mannose. The composition contains the bifidobacterium animalis probiotic strain, and contains / does not contain metabolites of the bifidobacterium animalis probiotic strain and one or more physiologically acceptable excipients or carriers. The method has the advantages that the protective strain lacked by the melanoma patient is screened and separated from the intestinal tract of a healthy person, the strain can normally survive in the intestinal tract of the human body and has no toxic or side effect, and a new way is provided for prevention and treatment of the melanoma patient by supplementing the lacked protective strain and active metabolites of the patient in a targeted manner; and an innovative solution is provided for auxiliary immunotherapy of melanoma.

A bone graft composition comprising a calcium phosphate putty is provided. A method of repairing a bone defect in a patient by applying the bone graft composition is also provided.

The invention discloses an aspirin enteric-coated micro-tablet capsule and a preparation method thereof. The micro-tablet core auxiliary materials of the enteric-coated micro-tablet capsule comprise an excipient, a disintegrating agent, a stabilizer, a flow aid and a lubricant. Tartaric acid is adopted as a stabilizer of aspirin, gel silicon dioxide is adopted as a flow aid, a moisture absorption agent and a swelling agent, and a direct powder tabletting method is adopted to prepare a micro-tablet core; the invention provides the aspirin enteric-coated micro-tablet capsule which is good in powder flowability, stable and easy to control in process, good in stability, uniform in dissolution and release characteristics, stable in blood concentration and high in bioavailability.

The invention relates to the technical field of pharmaceutical preparations, and provides an oral solid preparation for treating gout and a preparation method thereof. The preparation method comprises the following steps: sieving a filling agent, a disintegrating agent, an adhesive and dotenorad to obtain a sieved material; and mixing the sieved material and a lubricant, and tabletting to obtain the oral solid preparation for treating gout, the filling agent is lactose, mannitol and microcrystalline cellulose. By optimizing the prescription and the preparation process, the dissolution rate and bioavailability of the medicine are improved, so that the curative effect is improved; by selecting proper auxiliary materials and preparation types, the stimulation to gastrointestinal tracts is reduced, and the tolerance of patients is improved; the oral solid preparation is convenient to take, accurate in dosage, high in patient compliance and beneficial to long-term treatment; moreover, the preparation method provided by the invention is simple to operate, easy for industrial production and relatively low in cost.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to double-orange granules and a preparation method thereof. The double-orange granules comprise the following raw materials: a volatile oil inclusion compound, dry paste powder, low-viscosity dextrin, powdered sugar and amber powder. The volatile oil clathrate compound is prepared by the following steps: adding water into beta-cyclodextrin, uniformly mixing, and then adding volatile oil for clathration, thereby obtaining the volatile oil clathrate compound. The mass ratio of the beta-cyclodextrin to the water is 1: (4-6), the mass ratio of the volatile oil to the beta-cyclodextrin is 1: (9-12), and the dry paste powder is prepared by adding the double-orange particle extract into low-viscosity dextrin and carrying out spray drying. The preparation method of the double-orange granules comprises the following steps: mixing all the raw materials, granulating by taking a 55-65% ethanol water solution as an adhesive, finishing the granules, drying, and finishing the granules again. According to the invention, by optimizing the variety and dosage of the auxiliary materials, the tower sticking phenomenon in spray drying can be obviously improved, and the yield of spray drying and the particle yield of wet granulation are improved.

The invention discloses a colchicine external preparation with high intradermal residual quantity and percutaneous transmittance as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The invention provides a colchicine external preparation with high intradermal residue and transdermal transmittance. The colchicine external preparation comprises: a) colchicine or a pharmaceutically acceptable salt thereof; b) a penetration enhancer; c) pharmaceutically acceptable excipients and / or excipients; the penetration enhancer is at least one of polyglycerol oleate or isosorbide dimethyl ether. The drug loading capacity and the percutaneous transmittance of the colchicine external preparation disclosed by the invention are remarkably improved. When polyglycerol oleate is selected as a penetration enhancer to prepare colchicine gel, the intradermal retention volume can reach 358.08 micrograms within 20 hours. When isosorbide monomethyl ether is selected as a penetration enhancer to prepare ethosome gel, the accumulated penetration amount can reach 106.87 mu g / cm < 2 >, and the intradermal residual amount can reach 90.58 mu g or above.

Disclosed herein, in part, are liquid pharmaceutical formulations comprising furosemide or a pharmaceutically acceptable salt thereof, one or more pharmaceutically acceptable excipients, and a pharmaceutically acceptable buffer. Methods of treating congestion, edema, fluid overload, or hypertension in a patient in need thereof are also provided.

The invention provides microcapsule seasoning powder containing active plant components for cats and a preparation method of the microcapsule seasoning powder, the microcapsule seasoning powder comprises a double-layer embedding system, and the microcapsule seasoning powder comprises the following raw material components in percentage by weight: 10-14 wt% of a composite core material, 32-36 wt% of a multifunctional food calling base material, 35-39 wt% of the double-layer embedding system and 14-16 wt% of functional auxiliary materials; the composite core material is prepared by compounding a mint extract, a green tea extract, a chicory extract, a mulberry leaf extract and a hawthorn extract according to the mass ratio of (1.8-4.5): (1.2-3): (0.8-1.5): (0.5-1.2): (1-2). The cat food has a dual-stage targeting effect of low release in the stomach and high release in the intestinal tract, has high palatability, has the effects of promoting the health of the intestinal tract, improving metabolism and resisting aging synergistically, is long-acting and stable, and can be suitable for various types of functional foods for cats.

Disclosed are compositions comprising a lipid polymer excipient and AmB or an AmB derivative. The lipid polymer excipient can form micelles when formulated with AmB or the AmB derivative and can solubilize and stabilize the drug. Also disclosed are methods of treating a fungal infection using the compositions.

The present invention belongs to the technical field of plant extracts, and more specifically, relates to the use of a carob extract in a drug for improving glucose metabolism / polycystic ovary syndrome in women. The present invention discloses a pharmaceutical composition for improving glucose metabolism and treating polycystic ovary syndrome in women, the pharmaceutical composition comprising: carob extract, baicalein, cedrol, a bioactive peptide, a biopolysaccharide, and excipients. The composition of the present invention has the effects of lowering blood sugar and blood lipids, improving insulin function, and also has antioxidant and immunity-enhancing effects. By combining the above substances, a synergistic effect is achieved, further enhancing the effect of improving / treating polycystic ovary syndrome in women associated with abnormal glucose metabolism.